NASDAQ:ELOX Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis $17.19 -0.26 (-1.49%) As of 09/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsSEC Filings About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eloxx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$17.06▼$18.2550-Day Range$11.26▼$20.9852-Week Range$8.20▼$23.40Volume22,352 shsAverage Volume38,227 shsMarket Capitalization$69.45 millionP/E RatioN/ADividend YieldN/APrice Target$38.33Consensus RatingModerate Buy Company Overview Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing therapies for genetic diseases caused by nonsense mutations, which can prevent cells from producing functional proteins. The company’s research platform centered on ribosome modulation, an approach intended to encourage cells to read through certain premature stop signals in genetic instructions. Its lead product candidate, ELX-02, was an investigational small-molecule therapy designed to promote the production of full-length proteins in diseases associated with nonsense mutations. Eloxx evaluated ELX-02 primarily for cystinosis, a rare inherited disorder caused by mutations in the CTNS gene, and also explored potential applications in other genetic conditions, including cystic fibrosis. The company was formerly known as Zikani Therapeutics and conducted research and development activities in the United States and Israel, including work through its Israeli operations. Eloxx was a development-stage company and did not have an established portfolio of marketed products. Public information about its later operations and leadership is limited, and the company’s status changed substantially after its development programs were advanced.AI Generated. May Contain Errors. Read More Eloxx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreELOX MarketRank™: Eloxx Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 499th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingEloxx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEloxx Pharmaceuticals has a consensus price target of $38.33, representing about 123.0% upside from its current price of $17.19.Amount of Analyst CoverageEloxx Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eloxx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Eloxx Pharmaceuticals is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eloxx Pharmaceuticals is -11.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.96% of the float of Eloxx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEloxx Pharmaceuticals has a short interest ratio ("days to cover") of 0.55, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eloxx Pharmaceuticals has recently increased by 17.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEloxx Pharmaceuticals does not currently pay a dividend.Dividend GrowthEloxx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for ELOX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.Read more about Eloxx Pharmaceuticals' insider trading history. Receive ELOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELOX Stock News HeadlinesEloxx Pharmaceuticals (ELOX) vs. Its Peers Financial AnalysisSeptember 21 at 7:45 AM | americanbankingnews.comEloxx Pharmaceuticals (ELOX) & Its Rivals Financial ComparisonSeptember 21 at 6:45 AM | americanbankingnews.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end. | Banyan Hill Publishing (Ad)Head to Head Review: Eloxx Pharmaceuticals (ELOX) versus Its RivalsSeptember 20 at 2:14 AM | americanbankingnews.comFinancial Contrast: Eloxx Pharmaceuticals (ELOX) vs. Its RivalsSeptember 17, 2026 | americanbankingnews.comCritical Survey: Eloxx Pharmaceuticals (ELOX) versus Its PeersSeptember 14, 2026 | americanbankingnews.comEloxx Pharmaceuticals, Inc.: Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport SyndromeSeptember 11, 2026 | finanznachrichten.deEloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport SyndromeSeptember 11, 2026 | prnewswire.comSee More Headlines ELOX Stock Analysis - Frequently Asked Questions How have ELOX shares performed this year? Eloxx Pharmaceuticals' stock was trading at $0.0121 on January 22, 2026. Since then, ELOX stock has increased by 141,966.1% and is now trading at $17.19. How were Eloxx Pharmaceuticals' earnings last quarter? Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.66) earnings per share for the quarter. When did Eloxx Pharmaceuticals' stock split? Eloxx Pharmaceuticals's stock reverse split before market open on Monday, June 1st 2026.A 1-11 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 29th 2026. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split. When did Eloxx Pharmaceuticals IPO? Eloxx Pharmaceuticals (ELOX) raised $33 million in an initial public offering on Tuesday, June 9th 2026. The company issued 2,975,000 shares at $11.00 per share. How do I buy shares of Eloxx Pharmaceuticals? Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ELOX CIK1035354 Webwww.eloxxpharma.com Phone781-577-5300Fax908-864-4440Employees7Year FoundedN/APrice Target and Rating Average Price Target for Eloxx Pharmaceuticals$38.33 High Price Target$43.00 Low Price Target$32.00 Potential Upside/Downside+123.0%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$6.36 million Price / Sales10.92 Cash FlowN/A Price / Cash FlowN/A Book Value($85.17) per share Price / Book-0.20Miscellaneous Outstanding Shares4,040,000Free Float2,991,000Market Cap$69.45 million OptionableN/A Beta-1,862.26 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ELOX) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | SponsoredA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eloxx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eloxx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
